<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-UXLF9DNK/65f5f816-4049-4f37-946f-a6d24a4ec9bb/HTML"><dcterms:extent>25 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-UXLF9DNK/fef290d7-fbc0-41ab-b243-51a4ab771e24/PDF"><dcterms:extent>107 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-UXLF9DNK/8ae2ae84-c96a-4580-a0ba-1d92cf2d668f/TEXT"><dcterms:extent>22 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-UXLF9DNK"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2002</dcterms:issued><dc:creator>Brovet-Zupančič, Irena-Hedvika</dc:creator><dc:creator>Jančar, Boris</dc:creator><dc:creator>Logar, Primož</dc:creator><dc:creator>Novak-Andrejčič, Katrina</dc:creator><dc:format xml:lang="sl">letnik:71</dc:format><dc:format xml:lang="sl">str. II-67-II-70</dc:format><dc:format xml:lang="sl">številka:supl. 2</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:14711769</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-UXLF9DNK</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="en">Brachytherapy</dc:subject><dc:subject xml:lang="sl">Brahiterapija</dc:subject><dc:subject xml:lang="en">Choroid neoplasms</dc:subject><dc:subject xml:lang="sl">Horioidea, novotvorbe</dc:subject><dc:subject xml:lang="sl">Izid zdravljenja</dc:subject><dc:subject xml:lang="en">Melanom</dc:subject><dc:subject xml:lang="en">Melanoma</dc:subject><dc:subject xml:lang="sl">oftalmologija</dc:subject><dc:subject xml:lang="en">Radiotherapy</dc:subject><dc:subject xml:lang="en">therapy</dc:subject><dc:subject xml:lang="en">Treatment outcome</dc:subject><dc:subject xml:lang="sl">Vid, ostrina</dc:subject><dc:subject xml:lang="en">Visual acuity</dc:subject><dc:subject xml:lang="sl">zdravljenje</dc:subject><dc:subject xml:lang="sl">žilnica</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Zdravljenje malignega melanoma žilnice z brahiterapijo (Ru-106) - 14-letne izkušnje| Brachytherapy (Ru-106) for choroidal melanoma - our experience of 14 years|</dc:title><dc:description xml:lang="sl">Background. For many years, malignant melanoma of the choroid was treated withprompt enucleation. Recently several eye preserving methods have been developed. The aim of our study was to report on the therapeutic results in patients with primary choroidal melanoma treated with ruthenium-106 brachytherapy. Methods. A retrospective chart review of 65 patients treated with ruthenium-106 brachytherapy for choroidal melanoma from 1986 to 1997 was performed. The patients were 22 to 78 years old (mean 54.5 years). The height of the tumors was within the range of 1.5 to 7.1 mm (mean 4.7mm). The mean dose to the apex of the tumor was 100 Gy. Mean follow-up period was 90.6 months (range 22 to 169 months). Fundus photography, diagnostic ultrasound andbest corrected visual acuity were performed during each examination before and after radiation. Results.12 (18.4%) patients died from metastatic spread and 2 from other causes. Complete tumor regression occurred in 12 (18.4%) patients. Tumor regression was partial in 31 (47.7%) patients. Enucleation because of tumor growth was performed in 11(16.9%) patients and in 2 for otherreasons. 19 (30%) eyes retained visual acuity better than 0.5 and 49% of patients had visual acuity better than 0.1. Conclusions. Ruthenium brachytherapy has proved to be an effective conservative treatment for uveal melanomas thinner than 7mm. The present results correspond well with data in the literature. Visual outcome correlates with tumor location</dc:description><dc:description xml:lang="sl">Izhodišča. Do nedavno je bila enukleacija edini način zdravljenja malignega melanoma žilnice. Nove, t. i. konzervirajoče metode zdravljenja ohranijo oko in v različnem obsegu tudi njegovo funkcijo. Namen našega prispevka je predstaviti rezultate zdravljenja malignega melanoma žilnice z brahiterapijo (Ru-106). Metode. Retrospektivno smo analizirali zdravstveno dokumentacijo 30 moških in 35 žensk z malignim melanomom žilnice, ki so bili zdravljeni z brahiterapijo med letoma 1986 in 1997. Diagnozo primarnega melanoma žilnice smo postavili s pomočjo kliničnega pregleda, ehografije in pri nekaterih bolnikih s fluoresceinsko angiografijo. Bolniki so bili stari od 22 do 78 let (povprečno 54,5 leta). Višina tumorjev se je gibala med 1,5 in 7,1 mm (povprečno 4,7 mm). Vsi bolniki so bili na začetku zdravljenja brez ugotovljenih metastaz. Pri prvem operativnem posegu smo na mesto nad tumorjem na sklero prišili radioaktivni aplikator. Čas obsevanja smo izračunali tako, da je vrh tumorja prejel odmerek povprečno 100 Gy. Pri drugi operaciji smo aplikator odstranili. Bolnike smo sledili povprečno 90,8 meseca (od 22 do 169 mesecev). Pri vsakem kontrolnem pregledu smo določili vidno ostrino, posneli fotografijo ozadja in ehografsko izmerili višino tumorja. Bolniki so enkrat letno opravili internistični pregled z laboratorijskimi preiskavami in ultrazvočni pregled trebuha. Rezultati. 12 (18,4%) bolnikov je umrlo zaradi metastaz, 2 zaradi drugih bolezni. Tumorji so izginili pri 12 (18,4%) bolnikihdelni regres tumorjev pa je bil dosežen pri 31 (47, 7%) bolnikih. Pri 11 (16,9%) bolnikih smo se zaradi rasti tumorja odločili za enukleacijo, pri enem bolniku pa je bila enukleacija potrebna zaradi sekundarnega glavkoma, priše enem zaradi nejasnega stanja s slepoto.19 (30%) bolnikov je ohranilo vidno ostrino zdravljenega očesa več kot 0,5, pri 49% bolnikov je bila vidna ostrina večja od 0,1. (Izvleček prekinjen pri 2000 znakih)</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-UXLF9DNK"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-UXLF9DNK" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-UXLF9DNK/fef290d7-fbc0-41ab-b243-51a4ab771e24/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-UXLF9DNK/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-UXLF9DNK" /></ore:Aggregation></rdf:RDF>